Teriparatide biosimilar (Shanghai CAS Shenglongda Biotech)
重组人甲状旁腺素1-34 (Shanghai CAS Shenglongda Biotech)
Report date: 2022/01/14 13:23:58
Base Information
Drug NameTeriparatide biosimilar (Shanghai CAS Shenglongda Biotech)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesShanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A